EUVIMEDEUVIMED entdecken
Crossref

Overcoming cisplatin resistance in ovarian cancer: A novel approach via mitochondrial targeting peptide Pal-pHK-pKV

Yiqing Yuan, Junyi Zhang, Hongya Zeng, Ailin Gui, Yichen Yan, Aihua Zou, Ling Yang

Biochemical and Biophysical Research Communications · 2024

DOI: 10.1016/j.bbrc.2024.150616 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2024. Verfasst von Yiqing Yuan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Cisplatin, Drug Resistance, Neoplasm, Mitochondria. Die Arbeit nennt 19 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cisplatin (DDP) resistance in advanced stages of ovarian cancer significantly reduces survival rates. Mitochondria may serve as a potential therapeutic target for ovarian cancer. Pal-pHK-pKV is a mitochondrial targeting peptide synthesized by supramolecular assembly. Our study aims to investigate whether Pal-pHK-pKV serves as a useful strategy to reverse DDP resistance in ovarian cancer. Subcutaneous tumor implantation of the DDP-resistant ovarian cancer cell line A2780CP was conducted in nude mice, and drugs were administered intraperitoneally to compare the inhibitory effects of Pal-pHK-pKV and DDP on A2780CP cells in vivo. Combination index values were calculated for various concentrations of DDP and Pal-pHK-pKV to determine the optimal combination concentration. Mitochondrial membrane potential, cytochrome C distribution and immunofluorescence were also measured. Our studies demonstrated that Pal-pHK-pKV treatment reduced the proliferation, invasion and metastasis of ovarian cancer cells and impaired mitochondrial function. Furthermore, the combination of Pal-pHK-pKV and DDP exhibited a synergistic effect. Mechanistically, Pal-pHK-pKV can impair mitochondrial function, reduce mitochondrial membrane potential and release ROS. On the other hand, Pal-pHK-pKV can affect ERK pathway activation and inhibit tumor development. In conclusion, the mitochondria-specific amphiphilic peptide Pal-pHK-pKV provides a novel approach for treating ovarian cancer and may potentially overcome DDP drug resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsCisplatinDrug Resistance, NeoplasmMitochondriaMice, NudeAntineoplastic AgentsFemaleAnimalsHumansCell Line, TumorMiceOligopeptidesMembrane Potential, MitochondrialCell ProliferationXenograft Model Antitumor AssaysMice, Inbred BALB CPeptides

Stichwörter der Autor:innen

CisplatinERKMitochondriaOvarian cancerPal-pHK-pKV

Substanzen

CisplatinAntineoplastic AgentsOligopeptidesPeptidesarginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide

Autor:innen und Institutionen

  • Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, China.
  • College of Chemistry and Materials Science, Shanghai Normal University, Shanghai, China. Electronic address: aihuazou@shnu.edu.cn.
  • Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, China. Electronic address: yangling@fudan.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Yuan, Y., Zhang, J., Zeng, H., Gui, A., Yan, Y., Zou, A., & Yang, L. (2024). Overcoming cisplatin resistance in ovarian cancer: A novel approach via mitochondrial targeting peptide Pal-pHK-pKV. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2024.150616

Vancouver

Yuan Y, Zhang J, Zeng H, Gui A, Yan Y, Zou A, et al. Overcoming cisplatin resistance in ovarian cancer: A novel approach via mitochondrial targeting peptide Pal-pHK-pKV. Biochemical and Biophysical Research Communications. 2024. doi:10.1016/j.bbrc.2024.150616

BibTeX
@article{Yuan2024,
  author = {Yuan, Yiqing and Zhang, Junyi and Zeng, Hongya and Gui, Ailin and Yan, Yichen and Zou, Aihua and Yang, Ling},
  title = {Overcoming cisplatin resistance in ovarian cancer: A novel approach via mitochondrial targeting peptide Pal-pHK-pKV},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2024},
  doi = {10.1016/j.bbrc.2024.150616}
}
Kostenlos starten →